,,iii  #aag? ,,congress  #a/ ,session   
,s4 ,,res4 #baj  ,,9 ,,! ,,s5ate ,,( ,,!
 ,,unit$ ,,/ates  ,may #ab1 #bjba,mr4   
,graham 7= himself1 ,ms4 ,s9ema1 ,mr4   
,kelly1 ,mr4 ,coons1 ,ms4 ,w>r51 ,mr4   
,m>key1 ,mr4 ,rubio1 & ,mr4 ,w>nock7    
submitt$ ! foll[+ resolution2 :i* 0     
consid]$ & agre$ to  ,,resolution       
,designat+ ,july #ba1 #bjba1 z          
,gliobla/oma ,aw>5ess ,day4  ,:]eas     
approximately #ac1jjj new cases (       
gliobla/oma w be diagnos$ 9 ! ,unit$    
,/ates 9 #bjba2 ,:]eas gliobla/oma is-- 
7#a7 ! mo/ common malignant1 canc]\s    
bra9 tumor1 acc\nt+ = approximately half
 ( all prim>y malignant bra9 tumors2 &  
7#b7 ! mo/ aggressive1 complex1         
difficult to treat1 & deadly type ( bra9
 tumor2 ,:]eas x is e/imat$ t m ?an     
#aj1jjj individuals 9 ! ,unit$ ,/ates w 
succumb to gliobla/oma e ye>2 ,:]eas !  
#e-ye> survival rate = gliobla/oma      
pati5ts is only #g4b p]c5t & ! m$ian    
l5g? ( survival = gliobla/oma pati5ts is
 only #h mon?s2 ,:]eas gliobla/oma is   

describ$ z a disease t affects ! ess5ce 
( self1 z ! treatm5t & removal (        
gliobla/oma pres5ts significant *all5ges
 due to ! uniquely complex & fragile    
nature ( ! bra91 ! prim>y organ 9 !     
human body t controls n only cognitive  
ability b also ! actions ( e organ &    
limb2 ,:]eas1 relative to o!r types (   
canc]s1 bra9 canc] has-- 7#a7 ! highe/  
p]-pati5t initial co/ ( c>e1 ) an       
annualiz$ mean net co/ ( c>e approa*+   
#aej1jjj2 &  7#b7 ! highe/ annualiz$    
mean net co/s = la/-ye>-(-life c>e1 ) a 
co/ ( betwe5 #ace1jjj & #baj1jjj p]     
pati5t1 dep5d+ on ! age & g5d] ( a      
pati5t2 ,:]eas1 al?\gh rese>* advances  
may fuel ! developm5t ( new treatm5ts = 
gliobla/oma1 *all5g+ ob/acles to        
accel]at+ progress t[>d new treatm5ts = 
gliobla/oma rema9 & !re are no scre5+ or
 e>ly detection me?ods2 ,:]eas1 al?\gh  
gliobla/oma 0 fir/ describ$ 9 m$ical &  
sci5tific lit]ature 9 ! #aibjs1 &       
despite its deva/at+ prognosis1 only #d 
drugs & #a m$ical device h be5 approv$  

by ! ,food & ,drug ,adm9i/ration to     
treat gliobla/oma s9ce ! #aibjs & !     
mortality rates associat$ ) gliobla/oma 
h *ang$ little dur+ ! pa/ #cj ye>s2     
,:]eas1 z a promis+ fir/ /ep s9ce ! fir/
 ,gliobla/oma ,aw>5ess ,day1 ! ,national
 ,canc] ,in/itute e/abli%$ !            
,gliobla/oma ,!rapeutics ,network       
7ref]r$ to 9 ?is preamble z ,,gtn7 9    
#bjbj1 z "p ( a national infra/ructure  
to enhance & support ! discov]y &       
developm5t ( gliobla/oma !rapies1 ) an  
initial #f1jjj1jjj available =          
multi-in/itutional ,,gtn teams to drive 
!rapeutic ag5ts ?r\gh pre-cl9ical /udies
 & e>ly-phase cl9ical trials necess>y to
 rapidly evaluate pot5tial treatm5ts to 
advance t[>d cures & improv$ quality (  
life2 & ,:]eas !re is a ne$ = great]    
public aw>5ess ( gliobla/oma1 includ+   
aw>5ess ( bo?-- 7#a7 ! urg5t unmet      
m$ical ne$s ( gliobla/oma pati5ts2 &    
7#b7 ! opportunities = rese>* & treatm5t
 advances = gliobla/oma3 ,n[1 !re=e1 be 
x  ,t ! ,s5ate-- 7#a7 designates ,july  

#ba1 #bjba1 z ,gliobla/oma ,aw>5ess     
,day2  7#b7 enc\rages increas$ public   
aw>5ess ( gliobla/oma2  7#c7 honors !   
individuals :o h lo/ _! lives to        
gliobla/oma1 a deva/at+ disease1 or are 
curr5tly liv+ ) x2  7#d7 supports ef=ts 
to develop bett] treatm5ts = gliobla/oma
 t w improve ! long-t]m prognosis &     
quality ( life ( individuals diagnos$ ) 
! disease2  7#e7 expresses its support =
 ! individuals :o are battl+ bra9       
tumors1 z well z ! families1 fri5ds1 &  
c>egiv]s ( ^? individuals2  7#f7 urges a
 collaborative approa* to bra9 tumor    
rese>*1 :i* is a promis+ means ( advanc+
 ! und]/&+ & treatm5t ( gliobla/oma2 &  
7#g7 enc\rages cont9u$ inve/m5ts 9      
gliobla/oma rese>* & treatm5ts1 includ+ 
?r\gh ! ,gliobla/oma ,!rapeutics        
,network & o!r exi/+ bra9 tumor rese>*  
res\rces4